The most common misuse of hospital price data is treating it as a quality proxy. It isn’t. But the relationship between price and quality in healthcare is less random than its critics claim.
The naive version of the price-quality relationship in healthcare runs in both directions: some argue that higher-priced hospitals are better (the prestige assumption), while consumer advocates argue that transparency will push patients toward lower-cost alternatives without sacrificing quality (the competition assumption). Both are empirically contested. The Dartmouth Atlas’s decades of work on geographic variation in care intensity has documented that higher-cost regions produce no better, and sometimes worse, health outcomes than lower-cost regions—a finding that fundamentally challenges the prestige assumption at the population level.
At the individual hospital level, the evidence is more heterogeneous. High-volume hospitals performing complex procedures do, for several specific conditions and operations, produce better outcomes than lower-volume facilities. This is the empirical basis for certificate-of-need laws that concentrate cardiac surgery and transplantation at designated centers. The relationship does not, however, generalize across all services and may not hold at all for high-volume, lower-acuity procedures where outcomes are almost universally good regardless of facility.
MedPricer’s rate data becomes analytically powerful when paired with publicly available quality metrics. CMS publishes hospital-level data on readmission rates, surgical complication rates, hospital-acquired infection rates, and patient experience scores through Hospital Compare. Linking MedPricer’s negotiated rates to these quality indicators—a linkage that requires only a hospital identifier and some data manipulation—enables the analysis that patients, employers, and policy analysts actually need: not just what hospitals charge, but whether their charges bear any relationship to their quality performance.
Researchers at the National Bureau of Economic Research and at several schools of public health have used claims data and quality metrics to examine this relationship and found it to be, at best, weakly positive and highly procedure-specific. For the most common commercially insured procedures, there is little evidence that higher-priced hospitals produce meaningfully better outcomes. For complex tertiary care—advanced oncology, multi-organ transplant, complex cardiac surgery—the relationship is stronger but still not linear.
For a health journalist, this creates a specific angle: find the hospitals that are simultaneously high-cost (top quartile of MedPricer’s negotiated rates for common procedures) and poor-performing on quality metrics (bottom quartile of readmission rates, patient experience, or complication rates for the same procedure). These institutions are, in the technical language of healthcare economics, high-cost, low-value providers. They are the clearest cases for scrutiny—and they are identifiable using public data that requires no proprietary access.
The converse is equally interesting: hospitals that are low-cost by MedPricer’s rate data but high-performing on quality metrics. These institutions are often urban safety-net hospitals or health system members that have developed efficient care processes without the leverage to extract premium commercial rates. Their story—delivering good outcomes at lower prices—is as important as the high-cost, low-quality story, and it is told far less frequently.
What MedPricer cannot do is establish causation. A hospital’s high rate might reflect genuine clinical quality, market dominance, historical contract inertia, or some combination. Rate data without quality data is uninformative about value. Quality data without rate data is uninformative about cost. The combination is where the analysis begins—not where it ends.
